{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:12:06Z","timestamp":1788495126270,"version":"build-2803163510"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ctrv.2022.102381","type":"journal-article","created":{"date-parts":[[2022,3,19]],"date-time":"2022-03-19T11:52:37Z","timestamp":1647690757000},"page":"102381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Compliance to chemoradiation in squamous cell carcinoma of the anus"],"prefix":"10.1016","volume":"106","author":[{"given":"Asad","family":"Mahmood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel","family":"Bhuva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Fokas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Glynne-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.ctrv.2022.102381_b0005","first-page":"02064","article-title":"ESMO Guidelines Committee. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"S0923\u20137534","author":"Rao","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2022.102381_b0010","unstructured":"Muirhead R, Adams RA, Gilbert DC et al. National Guidance for IMRT in Anal Cancer: Version 3 \u2013 18\/04\/2016. Available online: http:\/\/analimrtguidance.co.uk\/national-anal-imrt-guidance-v3.pdf [accessed 15 January 2022]."},{"key":"10.1016\/j.ctrv.2022.102381_b0015","unstructured":"Benson AB, Venook AP, Al-Hawary MM et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Anal Carcinoma Version 1.2021 \u2013 February 16; 2021. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/anal.pdf [accessed 15 January 2022]."},{"issue":"3","key":"10.1016\/j.ctrv.2022.102381_b0020","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ijrobp.2007.03.010","article-title":"Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation","volume":"68","author":"Bese","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2022.102381_b0025","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2003.01.008","article-title":"An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer","volume":"21","author":"Adelstein","year":"2003","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ctrv.2022.102381_b0030","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1200\/JCO.2009.27.4498","article-title":"Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02","volume":"28","author":"Peters","year":"2010","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ctrv.2022.102381_b0035","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1200\/JCO.2009.25.9663","article-title":"Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix","volume":"29","author":"Duenas-Gonzalez","year":"2011","journal-title":"J Clin Oncol"},{"issue":"suppl-1","key":"10.1016\/j.ctrv.2022.102381_b0040","first-page":"E2151","article-title":"Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: a systematic review","volume":"38","author":"Strojan","year":"2016","journal-title":"Head Neck"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102381_b0045","doi-asserted-by":"crossref","first-page":"e18663","DOI":"10.1097\/MD.0000000000018663","article-title":"Weekly versus triweekly cisplatin-based concurrent chemoradiotherapy in the treatment of locally advanced cervical carcinoma: An updated meta-analysis based on randomized controlled trials","volume":"99","author":"Zhu","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102381_b0050","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.soc.2016.07.004","article-title":"Evolution and Management of Treatment-Related Toxicity in Anal Cancer","volume":"26","author":"Ludmir","year":"2017","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1016\/j.ctrv.2022.102381_b0055","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, Mitomycin and radiotherapy vs fluorouracil, cisplatin and radiotherapy for carcinoma of the anal canal: a randomised controlled trial","volume":"199","author":"Ajani","year":"2008","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102381_b0060","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ijrobp.2008.08.070","article-title":"Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas","volume":"74","author":"Myerson","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102381_b0065","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1016\/j.ijrobp.2012.01.023","article-title":"Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas","volume":"83","author":"Gay","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102381_b0070","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/jnci\/djt001","article-title":"Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials","volume":"105","author":"Ohri","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102381_b0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.radonc.2012.09.011","article-title":"Compliance with therapeutic guidelines in Radiation Therapy Oncology Group prospective gastrointestinal clinical trials","volume":"105","author":"Willett","year":"2012","journal-title":"Radiother Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102381_b0080","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/BF02553933","article-title":"An evaluation of combined therapy for squamous cell cancer of the anal canal","volume":"27","author":"Nigro","year":"1984","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.ctrv.2022.102381_b0085","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(96)03409-5","article-title":"Epidermoid Anal Cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil and Mitomycin","volume":"348","author":"UKCCCR Anal Cancer Working Party","year":"1996","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102381_b0090","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0167-8140(93)90076-K","article-title":"Chemoradiation therapy for anal cancer: radiation plus continuous infusion of 5-fluorouracil with or without cisplatin","volume":"27","author":"Rich","year":"1993","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102381_b0095","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2022.102381_b0100","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2x2 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102381_b0105","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1016\/j.ijrobp.2016.06.1006","article-title":"The Development of an Umbrella Trial (PLATO) to Address Radiation Therapy Dose Questions in the Locoregional Management of Squamous Cell Carcinoma of the Anus","volume":"96","author":"Sebag-Montefiore","year":"2016","journal-title":"Int J Radiation Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102381_b0110","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3109\/02841868809090333","article-title":"The hazard of accelerated tumor clonogen repopulation during radiotherapy","volume":"27","author":"Withers","year":"1988","journal-title":"Acta Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102381_b0115","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/lary.20072","article-title":"Poor radiotherapy compliance predicts persistent regional disease in advanced head\/neck cancer","volume":"119","author":"Patel","year":"2009","journal-title":"Laryngoscope"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102381_b0120","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/jmrs.183","article-title":"Assessing feasibility, compliance and toxicity of concomitant chemo-radiotherapy in head and neck cancers in the Northern Territory: initial experience and challenges","volume":"64","author":"Gupta","year":"2017","journal-title":"J Med Radiat Sci"},{"key":"10.1016\/j.ctrv.2022.102381_b0125","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102381_b0130","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.annonc.2020.06.012","article-title":"Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III ACT II trial","volume":"31","author":"Glynne-Jones","year":"2020","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102381_b0135","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1200\/JCO.1991.9.11.2042","article-title":"The calculation of actual or received dose intensity: a comparison of published methods","volume":"9","author":"Longo","year":"1991","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102381_b0140","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00277-007-0399-y","article-title":"Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP","volume":"87","author":"Bosly","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ctrv.2022.102381_b0145","first-page":"699","article-title":"Replacing 5-fluorouracil by capecitabine in localised squamous cell carcinoma of the anal canal: systematic review and meta-analysis","volume":"10","author":"Souza","year":"2016","journal-title":"E Cancer Med Sci"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102381_b0150","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.ijrobp.2018.04.033","article-title":"Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort","volume":"101","author":"Jones","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2022.102381_b0155","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"Bartelink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102381_b0160","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of Mitomycin in combination with Fluorouracil and radiotherapy and of salvage chemoradiation in the definitive nonsurgical treatment of Epidermoid Carcinoma of the Anal Canal: Results of a phase III randomized Intergroup Study","volume":"14","author":"Flam","year":"1996","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102381_b0165","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ijrobp.2014.06.061","article-title":"Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer","volume":"90","author":"Han","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"10.1016\/j.ctrv.2022.102381_b0170","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1016\/j.ejca.2009.06.020","volume":"45","author":"Matzinger","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102381_b0175","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.radonc.2012.06.006","article-title":"Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin","volume":"104","author":"Sebag-Montefiore","year":"2012","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102381_b0180","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s13566-017-0326-3","article-title":"Influence of radiation treatment technique on outcome and toxicity in anal cancer","volume":"6","author":"Fredman","year":"2017","journal-title":"J Radiat Oncol"},{"issue":"22","key":"10.1016\/j.ctrv.2022.102381_b0185","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1002\/cncr.31721","article-title":"Intensity-modulated radiotherapy improves survival and reduces treatment time in squamous cell carcinoma of the anus: A National Cancer Data Base study","volume":"124","author":"Elson","year":"2018","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102381_b0190","first-page":"e10989","article-title":"Patient Outcomes With Dose Escalation Using Modern Radiotherapy Techniques: A Retrospective Review of Anal Cancer Treated at a Large Academic Institution Between 2010 and 2016","volume":"12","author":"Murchison","year":"2020","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102381_b0195","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijrobp.2017.02.005","article-title":"Predictors of Radiation Therapy-Related Gastrointestinal Toxicity from Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529","volume":"98","author":"Olsen","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2022.102381_b0200","doi-asserted-by":"crossref","unstructured":"Kachnic L et al. Radiation Therapy Oncology Group RTOG 0529: A Phase II Evaluation of Dose-Painted IMRT in Combination with 5-Fluorouracil and Mitomycin-C for Reduction of Acute Morbidity in Carcinoma of the Anal Canal. Version Date: October 11; 2007. Available online: http:\/\/rpc.mdanderson.org\/rpc\/credentialing\/files\/0529.pdf [accessed 15 June 2021].","DOI":"10.1016\/j.ijrobp.2009.07.038"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102381_b0205","doi-asserted-by":"crossref","first-page":"882","DOI":"10.6004\/jnccn.2016.0093","article-title":"Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology","volume":"14","author":"Baden","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ctrv.2022.102381_b0210","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0360-3016(01)01510-3","article-title":"The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy","volume":"50","author":"Weber","year":"2001","journal-title":"Int J Radiation Oncol Biol Physic"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102381_b0215","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0360-3016(97)00329-5","article-title":"Time-dose considerations in the treatment of anal cancer","volume":"39","author":"Constantinou","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102381_b0220","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000071200","article-title":"Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy","volume":"65","author":"Graf","year":"2003","journal-title":"Oncology"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102381_b0225","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0360-3016(03)00417-6","article-title":"Results of definitive irradiation in a series of 305 epidermoid carcinomas of the anal canal","volume":"56","author":"Deniaud-Alexandre","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"15","key":"10.1016\/j.ctrv.2022.102381_b0230","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1002\/cncr.25901","article-title":"Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal","volume":"117","author":"Bazan","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2022.102381_b0235","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijrobp.2007.12.027","article-title":"Evaluation of planned treatment breaks during radiation therapy for anal cancer: Update of RTOG 92\u201308","volume":"72","author":"Konski","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102381_b0240","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.dld.2017.05.011","article-title":"Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP)","volume":"49","author":"Moureau-Zabotto","year":"2017","journal-title":"Dig Liver Dis"},{"issue":"34","key":"10.1016\/j.ctrv.2022.102381_b0245","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1200\/JCO.2010.29.1351","article-title":"Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87\u201304 and 98\u201311","volume":"28","author":"Ben-Josef","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102381_b0250","doi-asserted-by":"crossref","first-page":"277","DOI":"10.21037\/jgo.2020.02.09","article-title":"Impact of radiotherapy duration on overall survival in squamous cell carcinoma of the anus","volume":"11","author":"Mehta","year":"2020","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ctrv.2022.102381_b0255","doi-asserted-by":"crossref","first-page":"123","DOI":"10.6004\/jnccn.2010.0008","article-title":"Radiation therapy advances for treatment of anal cancer","volume":"8","author":"Pepek","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102381_b0260","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0360-3016(02)02833-X","article-title":"An evaluation of the relationship between the quality of prophylactic cranial radiotherapy in childhood acute leukemia and institutional experience: a quality assurance review center-pediatric oncology group study","volume":"53","author":"Halperin","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"20","key":"10.1016\/j.ctrv.2022.102381_b0265","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1002\/cncr.30843","article-title":"Treatment at high-volume facilities and academic centers is independently associated with improved survival in patients with locally advanced head and neck cancer","volume":"123","author":"David","year":"2017","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102381_b0270","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.clon.2016.10.005","article-title":"Initial Results from the Royal College of Radiologists' UK National Audit of Anal Cancer Radiotherapy 2015","volume":"29","author":"Muirhead","year":"2017","journal-title":"Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102381_b0275","doi-asserted-by":"crossref","first-page":"166","DOI":"10.4103\/ijc.IJC_517_17","article-title":"Compliance to radiotherapy: A tertiary care center experience","volume":"55","author":"Gupta","year":"2018","journal-title":"Indian J Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102381_b0280","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.ijrobp.2009.05.071","article-title":"Radiation dose-volume effects in the stomach and small bowel","volume":"76","author":"Kavanagh","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10.1016\/j.ctrv.2022.102381_b0285","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/j.clon.2016.04.044","article-title":"Pelvic Organ Motion during Radiotherapy for Cervical Cancer: Understanding Patterns and Recommended Patient Preparation","volume":"28","author":"Eminowicz","year":"2016","journal-title":"Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102381_b0290","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.ijrobp.2007.08.074","article-title":"Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy","volume":"70","author":"Mell","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102381_b0295","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.3390\/cancers12113306","article-title":"Bone Marrow-Sparing IMRT in Anal Cancer Patients Undergoing Concurrent Chemo-Radiation: Results of the First Phase of a Prospective Phase II Trial","volume":"12","author":"Arcadipane","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102381_b0300","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/ajco.12768","article-title":"Image-guided IMRT with simultaneous integrated boost as per RTOG 0529 for the treatment of anal cancer","volume":"14","author":"Arcadipane","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102381_b0305","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.radonc.2019.08.016","article-title":"Response of FDG avid pelvic bone marrow to concurrent chemoradiation for anal cancer","volume":"143","author":"Robinson","year":"2020","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102381_b0310","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijrobp.2018.05.044","article-title":"Intensity Modulated Radiation Therapy Versus Conventional Radiation for Anal Cancer in the Veterans Affairs System","volume":"102","author":"Bryant","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102381_b0315","doi-asserted-by":"crossref","first-page":"e1272","DOI":"10.1200\/OP.20.00343","article-title":"Placard in hand. A Simple, Inexpensive Intervention to Improve On-Treatment Visit Compliance in a Safety Net Radiation Oncology Patient Population","volume":"16","author":"Moeller","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102381_b0320","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ijrobp.2010.11.039","article-title":"Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704\u2013a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas","volume":"82","author":"Abrams","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102381_b0325","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/lary.20963","article-title":"Head and neck radiotherapy compliance in an underserved patient population","volume":"120","author":"Sethi","year":"2010","journal-title":"Laryngoscope"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102381_b0330","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.clon.2008.05.003","article-title":"Royal College of Radiologists Clinical Audit Subcommittee. The management of interruptions to radiotherapy in head and neck cancer: an audit of the effectiveness of national guidelines","volume":"20","author":"James","year":"2008","journal-title":"Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102381_b0335","doi-asserted-by":"crossref","first-page":"455","DOI":"10.48095\/ccko2021455","article-title":"Clinical application of time factor principles in radiotherapy in compensation of radiation series interruptions","volume":"34","author":"Pecha\u010dov\u00e1","year":"2021","journal-title":"Klin Onkol"},{"key":"10.1016\/j.ctrv.2022.102381_b0340","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejca.2019.08.022","article-title":"Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC)","volume":"121","author":"Rivin Del Campo","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2022.102381_b0345","unstructured":"WHO. Adherence to long-term therapies evidence for action. Version Date; 2003. Available online: https:\/\/www.who.int\/chp\/knowledge\/publications\/adherence_full_report.pdf [access 03 March 2022]."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102381_b0350","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4103\/psychiatry.IndianJPsychiatry_24_17","article-title":"Treatment compliance and noncompliance in psychoses","volume":"59","author":"Rao","year":"2017","journal-title":"Indian J Psychiatry"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102381_b0355","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/00000658-200006000-00013","article-title":"Patient compliance is critical for equivalent clinical outcomes for breast cancer treated by breast-conservation therapy","volume":"231","author":"Li","year":"2000","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctrv.2022.102381_b0360","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.radonc.2020.08.002","article-title":"Impact of non-adherence to radiotherapy on 1-year survival in cancer patients in Catalonia","volume":"151","author":"Borras","year":"2020","journal-title":"Spain Radiother Oncol"},{"issue":"35","key":"10.1016\/j.ctrv.2022.102381_b0365","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI intergroup RTOG 98\u201311 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102381_b0370","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.radonc.2015.07.014","article-title":"A tumor control probability model for anal squamous cell carcinoma","volume":"116","author":"Muirhead","year":"2015","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102381_b0375","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.radonc.2018.06.007","article-title":"Determinants for local tumour control probability after radiotherapy of anal cancer","volume":"128","author":"Johnsson","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctrv.2022.102381_b0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0009-9260(69)80043-7","article-title":"Dose, time and fractionation: a clinical hypothesis","volume":"20","author":"Ellis","year":"1969","journal-title":"Clin Radiol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102381_b0385","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0360-3016(92)90768-D","article-title":"Loss of local control with prolongation in radiotherapy","volume":"23","author":"Fowler","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctrv.2022.102381_b0390","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/02841868809090328","article-title":"Repopulation in human tumors: A biological background for fractionation in radiotherapy","volume":"27","author":"Tubiana","year":"1988","journal-title":"Acta Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102381_b0395","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.rpor.2015.05.010","article-title":"Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: review of the literature","volume":"20","author":"Gonzalez Ferreira","year":"2015","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.ctrv.2022.102381_b0400","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2407-6-28","article-title":"A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck","volume":"6","author":"Budach","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2022.102381_b0405","unstructured":"RCR. Timely delivery of radical radiotherapy: guidelines for the management of unscheduled treatment interruptions, fourth edition - BFCO(19)1. Version Date; 2019. Available online: https:\/\/www.rcr.ac.uk\/system\/files\/publication\/field_publication_files\/bfco191_radiotherapy-treatment-interruptions.pdf [accessed 03 March 2022]."},{"issue":"1","key":"10.1016\/j.ctrv.2022.102381_b0410","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1186\/s12885-021-08183-y","article-title":"Impact of relative dose intensity of oxaliplatin in adjuvant therapy among stage III colon cancer patients on early recurrence: a retrospective cohort study","volume":"21","author":"\u017bok","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2022.102381_b0415","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211029825","article-title":"FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma","volume":"13","author":"Vary","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ctrv.2022.102381_b0420","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1200\/JCO.2007.12.0170","article-title":"Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience","volume":"25","author":"Salama","year":"2007","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2022.102381_b0425","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.3390\/cancers13112533","article-title":"Volumetric Modulated Arc Therapy Improves Outcomes in Definitive Radiochemotherapy for Anal Cancer Whilst Reducing Acute Toxicities and Increasing Treatment Compliance","volume":"13","author":"Possiel","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2022.102381_b0430","doi-asserted-by":"crossref","first-page":"438","DOI":"10.5694\/j.1326-5377.2003.tb05627.x","article-title":"Inclusion of patients in clinical trial analysis: the intention-to-treat principle","volume":"179","author":"Heritier","year":"2003","journal-title":"Med J Aust"},{"key":"10.1016\/j.ctrv.2022.102381_b0435","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/gyno.1993.1184","article-title":"Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin","volume":"50","author":"Cornelison","year":"1993","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102381_b0440","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1186\/s12885-019-6233-9","article-title":"Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin","volume":"19","author":"van der Vorst","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2022.102381_b0445","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","article-title":"Antiemetics: American Society of Clinical Oncology clinical practice guideline update","volume":"29","author":"Basch","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102381_b0450","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s10157-017-1448-z","article-title":"Guidelines for treatment of renal injury during cancer chemotherapy 2016","volume":"22","author":"Horie","year":"2018","journal-title":"Clin Exp Nephrol"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102381_b0455","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","article-title":"A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity","volume":"22","author":"Crona","year":"2017","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102381_b0460","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3390\/jcm8081211","article-title":"Nutrition in Cancer Patients","volume":"8","author":"Ravasco","year":"2019","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102381_b0465","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0959-8049(97)10090-9","article-title":"Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?","volume":"34","author":"Andreyev","year":"1998","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102381_b0470","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/annonc\/mdy114","article-title":"Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for design of future trials","volume":"29","author":"de van der Schueren","year":"2018","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102381_b0475","doi-asserted-by":"crossref","first-page":"396","DOI":"10.62347\/SSQP7131","article-title":"Evidence-based nursing intervention can improve the treatment compliance, quality of life and self-efficacy of patients with lung cancer undergoing radiotherapy and chemotherapy","volume":"14","author":"Zhang","year":"2022","journal-title":"Am J Transl Res"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102381_b0480","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.clnu.2006.01.020","article-title":"ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology","volume":"25","author":"Arends","year":"2006","journal-title":"Clin Nutr"},{"key":"10.1016\/j.ctrv.2022.102381_b0485","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.3945\/ajcn.111.018838","article-title":"Dietary individualized counseling benefits in colorectal cancer: The long term follow-up of a randomized controlled trial of nutritional therapy","volume":"96","author":"Ravasco","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.ctrv.2022.102381_b0490","first-page":"1","article-title":"Enhancing patient adherence to improve outcomes with oral chemotherapy","volume":"32","author":"Boyle","year":"2007","journal-title":"US Pharm"},{"key":"10.1016\/j.ctrv.2022.102381_b0495","first-page":"124","article-title":"Adherence to oral cancer therapies: challenges and opportunities","author":"Partridge","year":"2009","journal-title":"American Society of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102381_b0500","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.ijrobp.2018.11.050","article-title":"Automated Text Message Reminders Improve Radiation Therapy Compliance","volume":"103","author":"Tan","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222000457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222000457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:27:25Z","timestamp":1759656445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737222000457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":100,"alternative-id":["S0305737222000457"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102381","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Compliance to chemoradiation in squamous cell carcinoma of the anus","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102381","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102381"}}